Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Korea Omega Investment Corp. was founded in April 2015 with an initial capital of 20 billion KRW and is registered as a new technology finance investment firm. In August 2017, it merged with Korea Omega Co., Ltd., raising its capital to 57 billion KRW. The firm is affiliated with KISWEL and has expanded its investment scope to include foreign exchange operations since June 2019.
Korea Omega Investment Corp. invests in early-stage ventures, growth capital, private equity, and buyouts across various sectors including biotech, fintech, and healthcare. The firm targets both domestic and international markets, investing in companies ranging from startups to publicly listed firms. Check sizes vary based on the stage and potential of the company.
Korea Omega Investment Corp. has backed notable companies such as SimfilBio, which develops high-precision liquid biopsy kits for cancer diagnosis, and b.able Company, a drama production and commerce-integrated publisher. Other investments include BioArchers, focusing on next-generation oral obesity drugs, and CellArk Bio, which develops medical aesthetic products.
Submit your pitch through their form at koreaomega.co.kr or email ckpark@koreaomega.co.kr with your deck.
Yes, Korea Omega Investment Corp. often leads investment rounds, particularly in early-stage ventures where they can provide strategic support.
The firm is open to follow-on investments, especially for portfolio companies demonstrating strong growth and potential.
The firm currently manages assets totaling 57 billion KRW following its merger in 2017.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.